0000911916-20-000136.txt : 20200622 0000911916-20-000136.hdr.sgml : 20200622 20200622195224 ACCESSION NUMBER: 0000911916-20-000136 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200622 FILED AS OF DATE: 20200622 DATE AS OF CHANGE: 20200622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McAvoy David R. CENTRAL INDEX KEY: 0001758842 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21088 FILM NUMBER: 20980066 MAIL ADDRESS: STREET 1: C/O ENDOCYTE, INC., 3000 KENT AVENUE STREET 2: SUITE A1-100 CITY: WEST LAFAYETTE STATE: IN ZIP: 47906 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Brickell Biotech, Inc. CENTRAL INDEX KEY: 0000819050 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 930948554 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (720) 505-4755 MAIL ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: VICAL INC DATE OF NAME CHANGE: 19940211 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2020-06-22 0000819050 Brickell Biotech, Inc. BBI 0001758842 McAvoy David R. C/O BRICKELL BIOTECH, INC. 5777 CENTRAL AVENUE, SUITE 102 BOULDER CO 80301 0 1 0 0 General Counsel and CCO Common Stock 2020-06-22 4 P 0 30435 A 59357 D Common Stock Warrants (right to buy) 1.25 2020-06-22 4 P 0 30435 A 2020-06-22 2025-06-22 Common Stock 30435 30435 D The reported securities were purchased by the reporting person at a combined public offering price of $1.15 per share of common stock and accompanying warrant exercisable for one share of common stock. Exhibit 24 - Power of Attorney /s/ Christine G. Long, Attorney-in-Fact for David R. McAvoy (power of attorney filed herewith) 2020-06-22 EX-24 2 mcavoybbipoa.htm POWER OF ATTORNEY
POWER OF ATTORNEY



For Executing Form ID and Forms 3, 4, 5 and 144



The undersigned hereby constitutes and appoints each of Daniel Boeglin, Jonathan Zimmerman, Christine Long,

Griffin Foster and Justin Hay, signing singly, as his true

and lawful attorney-in-fact, for such period of time that the

undersigned is required to file reports pursuant to

Section 16(a) of the Securities Exchange Act of

1934, as amended (the "Exchange Act"), or Rule 144 of the

Securities Act of 1933, as amended (the "Securities Act"),

due to his affiliation with Brickell Biotech, Inc., a

Delaware corporation, unless earlier revoked by the undersigned

in a signed writing delivered to the foregoing

attorneys-in-fact, to:



1) prepare, execute in the undersigned's name and on the

undersigned's behalf, and submit to the U.S. Securities

and Exchange Commission (the "SEC") a Form ID, including

amendments thereto, and any other documents necessary or

appropriate to obtain codes and passwords enabling the

undersigned to make electronic filings with the SEC of

reports required by Section 16(a) of the Exchange Act

or any rule or regulation of the SEC;



2) prepare, execute in the undersigned's name and on the

undersigned's behalf, and submit to the SEC Forms 3, 4, 5

and 144 and any amendments to previously filed forms in

accordance with Section 16(a) of the Exchange Act or Rule

144 of the Securities Act and the rules thereunder;



3) do and perform any and all acts for and on behalf of

the undersigned which may be necessary or desirable to

complete the execution of any such Form ID or Forms 3, 4,

5 and 144 and the timely filing of such form with the SEC

and any other authority as required by law; and



4) take any other action of any type whatsoever in connection

with the foregoing which, in the opinion of such

attorney-in-fact, may be of benefit to, in the best

interest of or legally required by the undersigned,

it being understood that the documents executed by such

attorney-in-fact on behalf of the undersigned pursuant to

this Power of Attorney shall be in such form and shall contain

such terms and conditions as such attorney-in-fact may approve

in his or her discretion.



The undersigned hereby grants to each such attorney-in-fact

full power and authority to do and perform all and every act

and thing whatsoever requisite, necessary and proper to be done

in the exercise of any of the rights and powers herein granted,

as fully to all intents and purposes as the undersigned could do

if personally present, with full power of substitution or revocation,

hereby ratifying and confirming all that such attorney-in-fact,

or his or her substitute or substitutes, shall lawfully do or cause

to be done by virtue of this Power of Attorney and the rights and

powers herein granted.  The undersigned acknowledges that the

foregoing attorneys-in-fact, in serving in such capacity at the

request of the undersigned, are not assuming any of the undersigned's

responsibilities to comply with Section 16 of the Exchange

Act or Rule 144 of the Securities Act.



The undersigned hereby revokes all other powers of attorney previously

executed in connection with the undersigned's obligations as an

officer, director and/or 10% shareholder of Brickell Biotech, Inc.

to prepare and file Forms 3, 4 and 5, or other forms or reports, or

any amendment or amendments thereto, with the SEC pursuant to Section

16(a) of the Exchange Act or Rule 144 of the Securities Act, or to

obtain or update codes with respect to electronic filings to be

made by the undersigned with the SEC.



IN WITNESS WHEREOF, the undersigned has caused this Power of

Attorney to be executed as of this 22nd day of June, 2020.



/s/ David McAvoy

David McAvoy